We enable cancer care for patients
Novasep CDMO, part of Axplora, strengthens its innovative position in oncology to enable cancer care for patients: €8M investment on its Le Mans (Fr) site, with the support of the France 2030 program, to expand its production capabilities for the manufacturing of ADCs. Behind every pharma project, there are high-quality services for our customers and cutting-edge drugs for millions of patients worldwide.Read the new press release
We are experts at finding solutions managing complexity, exploring new ways to meet our customers' needs. We are agile and responsive and we strive to provide the highest quality manufacturing solutions that will enable our customers to improve the quality of life of their patients.
Axplora offers a full range of reliable CDMO services for pharmaceutical innovators at a comprehensive range of production scales, based on an unrivalled spectrum of technologies.
Axplora is a global leader in manufacturing non-sterile and sterile steroids as well as a leading supplier of specialty API products and anticancer drugs. Our portfolio has +100 generic APIs commercially available, of which about 20 patent product families protected, and +150 active DMFs in eCTD format. Explore our products portfolio!
Axplora offers more than 15 differentiating technologies and is acknowledged as a world leader in a number of areas including hazardous chemistry, industrial chromatography, electrochemistry, steroids and ADCs, and supported by an extensive toolbox of classical chemistry.
Our Environmental, social, and corporate governance initiatives are an essential part of our reliable strategy.
The ESG roadmap is based on 5 main pillars: Health and safety, climate change, energy management, waste management, and diversity & inclusion.
drop in the number of accidents with lost time (TF1) in 2022 compared to 2021
drop in the number of accidents without lost time (TF2) in 2022 compared to 2021
of the Group's electricity consumption is renewable to make a positive change for our planet!
of women in the company, and 31% of managers are women